The 15th case of the novel coronavirus (COVID-19) was confirmed in the United States on Thursday, 1 and experts are expressing concerns that the outbreak in China could result in drug shortages in the US. Coronavirus Update -Plaquenil Shortages, IVIG and Ibuprofen March 26, 2020 March 26, 2020 Category: In The News On March 19, it was announced that chloroquine and hydroxychloroquine were showing promise in the treatment for COVID 19. Yes. Discontinuations Listed by Generic Name or Active Ingredient. Why is there an IVIG shortage and how long is it expected to last? Ask the Experts. The Food and Drug Administration (FDA) confirms that the demand for IVIG products has increased over recent years and along with production and distribution issues, an ongoing shortage of IVIG products across the United States will exist through April 2020. A shortage of a versatile medicine used to treat immune disorders and other diseases has forced U.S. hospitals and infusion clinics to suspend treatment for many patients. According to the World Health Organization (WHO), there are now over 63,500 cases globally. The COVID‐19 pandemic has introduced additional stress on the plasma supply. I have been receiving Gammagard for over 2 years and had to receive two cycles of Gammunex C until the Gammagard came available 3 weeks ago. 2 There have been 1381 deaths in China, including 100 reported on Friday. Companies are working hard to make more IVIG, but the shortage may last until 2020. In view of worldwide shortage of IVIG, priority should be given to the patients whose survival is dependent on IVIG while continuing the investigation on COVID‐19. The shortage of immunoglobulin products, announced earlier this summer, is impacting neurology patients in different parts of the country. Neurologists are addressing the shortage in different ways—from tiering and triaging the most urgent cases, to switching brands and dosing. The 2019 shortage of IVIG showed the fragility of the system. Also, IVIG is a life‐saving drug for primary immunodeficient patients and first‐line therapy for many autoimmune and inflammatory diseases. 6 days, 16 hours ago. • The Intravenous Immune Globulin (IVIG) Demonstration: Demonstration is ending on December 31, 2020 • October 2020 Integrated Outpatient Code Editor (I/OCE) Specifications Version 21.3 • October Quarterly Update for 2020 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Fee Schedule Reader: Can intravenous immune globulin therapy be started if a person has a current infection? We do not know the cause of the shortage. ... 2020 Medications for post CIDP by Hedley LaMarr. The IVIG shortage occurs various times each year and my understanding is that shortage is coming to an end. Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (as amended by the Food and Drug Administration Safety and Innovation Act) to notify FDA of a permanent discontinuance of certain drug products, six months in advance, or if that is not possible, as soon as practicable. Is the IVIG shortage affecting Mass General patients?